Predicting that the “demand for factory-scale sequencing of the human genome is about to explode,” Illumina CEO Jay Flatley backed up his contention with the announcement at the J.P. Morgan Healthcare ...

The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country. It’s part ...

The NovaSeq X Series is Illumina's most powerful sequencing system, delivering an unprecedented combination of high throughput and accuracy, and featuring streamlined informatics, breakthrough ...

San Diego-based Illumina, a global leader in genomic sequencing technology, unveiled its latest machines that could make analyzing genetics cheaper, more efficient and more accessible to researchers.

llumina on Thursday forecast core business revenue to be nearly flat in the coming year compared to 2023 amid subdued demand for its genetic testing tools and diagnostics products. The San Diego-based ...

Illumina (NASDAQ:ILMN) on Monday lowered its adjusted profit outlook and cut spending costs for 2025 as the company grapples with a Chinese ban on its gene sequencers. Illumina now expects fiscal 2025 ...

Illumina’s announced partnerships with IBM’s Watson and Philips help shore up the firm's data-analysis capabilities and clinical diagnostic marketing efforts, respectively, but the announcement of a ...

Most biopharma players need access to gene sequencing services. Illumina is facing a handful of headwinds, but it's still the market leader. Bionano Genomics is unproven but expanding quickly. So ...

Why Illumina’s Latest Move Has Investors Watching Closely Illumina (ILMN) just deepened its bet on clinical whole genome sequencing by investing in and partnering with MyOme, backing a large Proactive ...

Pacific Biosciences, a Menlo Park, Calif., firm best known for its niche approach to DNA sequencing, on Tuesday announced plans to launch a new product that will put the company in direct competition ...

Illumina Inc. introduced a new line of gene-sequencing machines that the company says can more than double capacity versus prior sequencers, while reducing the cost per genome. The rollout, which ...